Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24765275 | 0.91 | L3MBTL1 (0.55) | MTNR1AMTNR1BL3MBTL1NPC1RAB9A | |
| SCHEMBL9765684 | 0.91 | L3MBTL1 (0.55) | MTNR1AMTNR1BL3MBTL1PTGS1NPC1 | |
| SCHEMBL2400875 | 0.87 | L3MBTL1 (0.59) | MTNR1AMTNR1BL3MBTL1PTGS1NPC1 | |
| SCHEMBL6312058 | 0.85 | MTNR1A (0.51) | MTNR1AMTNR1BL3MBTL1NPC1RAB9A | |
| SCHEMBL18978189 | 0.85 | L3MBTL1 (0.50) | MTNR1AMTNR1BL3MBTL1PTGS1NPC1 | |
| SCHEMBL8534165 | 0.85 | L3MBTL1 (0.50) | MTNR1AMTNR1BL3MBTL1PTGS1NPC1 | |
| SCHEMBL18978188 | 0.83 | L3MBTL1 (0.48) | MTNR1AMTNR1BL3MBTL1PTGS1NPC1 | |
| SCHEMBL10382783 | 0.83 | L3MBTL1 (0.48) | MTNR1AMTNR1BL3MBTL1PTGS1NPC1 | |
| SCHEMBL29014520 | 0.81 | L3MBTL1 (0.52) | MTNR1AMTNR1BL3MBTL1AOC3TDP1 | |
| SCHEMBL22917042 | 0.80 | MTNR1A (0.56) | MTNR1AMTNR1BL3MBTL1PTGS1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682938-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-3148972-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | Cardioxyl Pharmaceuticals Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015183839-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-12-03 | — | — | US | disclosed |
| EP-1109802-A1 | SPIROFLUORENOPYRANS | Optische Werke G. Rodenstock (DE) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002384-A1 | SPIROFLUORENOPYRANS | OPTISCHE WERKE G. RODENSTOCK (DE) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | MTNR1A 2060/4885MTNR1B 1842/4885L3MBTL1 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.